Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01257919
Recruitment Status : Completed
First Posted : December 10, 2010
Last Update Posted : April 1, 2020
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:

Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel.

Assessment of safety after repeated skin application.

Condition or disease Intervention/treatment Phase
Papulopustular Rosacea Drug: Azelaic Acid Foam Drug: Azelaic Acid Gel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Investigator-blinded, Randomized, Cross-over, Multiple Dose Phase I Study on Safety and Pharmacokinetics of Topically Applied Azelaic Acid Foam, 15% Compared to Azelaic Acid Gel, 15% in Subjects With Papulopustular Rosacea
Study Start Date : January 2011
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Rosacea
MedlinePlus related topics: Rosacea

Arm Intervention/treatment
Experimental: Azelaic Acid Foam 15%
Dermal application of Azelaic Acid Foam 15%
Drug: Azelaic Acid Foam
Dermal application of Azelaic Acid Foam

Active Comparator: Azelaic Acid Gel 15%
Dermal application of Azelaic Acid Gel 15%
Drug: Azelaic Acid Gel
Dermal application of Azelaic Acid Gel

Primary Outcome Measures :
  1. Baseline corrected area under the curve (AUC) [ Time Frame: 12 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of moderate papulopustular rosacea
  • free of any clinically significant disease

Exclusion Criteria:

  • body weight less than 50 or more than 130 kg
  • clinically significant disease which could interfere with the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01257919

Layout table for location information
United States, Nevada
Novum Pharmaceutical Research Services of Nevada Inc.
Las Vegas, Nevada, United States, 89121
Sponsors and Collaborators
LEO Pharma
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: LEO Pharma Identifier: NCT01257919    
Other Study ID Numbers: 15386
1401843 ( Other Identifier: Company Internal )
First Posted: December 10, 2010    Key Record Dates
Last Update Posted: April 1, 2020
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Azelaic acid
Antineoplastic Agents
Dermatologic Agents